--- title: Generate:Biomedicines slug: generatebiomedicines-ae491 url: /detay/generatebiomedicines-ae491 type: article language: English entity: primary: Generate:Biomedicines type: article categories: - name: Science And Technology slug: bilim url: /kategori/bilim - name: Engineering slug: muhendislik url: /kategori/muhendislik - name: Technology And Innovation slug: teknoloji url: /kategori/teknoloji tags: - GenerateBiomedicines author: Ömer Said Aydın created_at: 2025-10-25T15:40:27.741546+03:00 updated_at: 2025-11-12T16:13:59.525180+03:00 image: https://cdn.t3pedia.org/media/uploads/2025/10/25/bFoa01OZQZoFZ9367Ue0fZJbqfvBnx21.jpg --- # Generate:Biomedicines ## KURE Information Cards ![generate_biomedicines_logo.jpg](https://cdn.t3pedia.org/media/uploads/2025/10/25/DaAXi0yMtpZL7gV9xZ1ikLOLw2JKkwhf.jpg) *GenerateBiomedicines* | Field | Value | |-------|-------| | Website(s) | https://www.generatebiomedicines.com | | Founded(Text) | 2020 | | Headquarters | Somerville, Massachusetts, United States | | Co-Founders | Molly Gibson Gevorg Grigoryan | | Founding Purpose | Systematic programming and production of protein-based therapeutics through AI-enabled bioengineering. | | Scientific Approach | Generative Biology™, the design and synthesis of novel protein sequences not found in nature, based on statistical and computational analysis of biological structures. | ## Article Content [Generate:Biomedicines](/en/detay/generatebiomedicines-4394e/llms.txt) is a next-generation biotechnology company integrating machine learning, bioengineering, and medicine to revolutionize therapeutic protein design. Through its proprietary Generative Biology™ approach, the company enables the *programming* of protein-based therapeutics, fundamentally transforming the way drugs are discovered and developed. Headquartered in Somerville, [Massachusetts](/en/detay/massachusetts-institute-of-technology-58be4/llms.txt), Generate:Biomedicines is a venture of Flagship Pioneering, founded on the principle that biological systems are programmable and can be systematically engineered to produce therapeutic proteins. ### **Generative Biology™ Approach** Generative Biology™ represents a data-driven and computational framework that moves beyond trial-and-error methods in drug development. This approach extracts generalizable biological principles from the sequence and structural data of millions of natural proteins. Using advanced machine learning algorithms, Generate:Biomedicines models the relationships between amino acid sequences, protein structure, and biological function to create *novel protein sequences* not found in nature. These insights allow the company to design proteins with specific therapeutic properties—including antibodies, enzymes, gene therapy components, and complex protein architectures—which can be precisely tailored for diverse clinical applications. At the core of this process lies the **Generate Platform**, built upon a **“Generate–Build–Measure–Learn”** cycle: 1. **Generate:** Algorithms propose protein sequences designed to address defined therapeutic questions. 2. **Build:** The sequences are synthesized and expressed in laboratory systems. 3. **Measure:** The physical and functional properties of the proteins are evaluated. 4. **Learn:** The resulting data feed back into the algorithms, continually improving model accuracy. This iterative framework enables the **rapid and systematic validation** of newly designed proteins, significantly reducing drug discovery timelines. ### **Research and Development Focus** Generate:Biomedicines’ research programs focus on **immunology**, **oncology**, and **infectious diseases**. Its clinical-stage pipeline includes: - **GB-0895** for asthma - **GB-7624** for atopic dermatitis - **GB-6537** for ulcerative colitis - **GB-0669** for COVID-19 The company also collaborates with major pharmaceutical partners such as **Novartis** and **Amgen** on multiple co-development projects. In addition, Generate is pioneering the design of **de novo protein–protein interactions** and **immune-evasive proteins**, expanding the frontiers of therapeutic biology. ### **Leadership** Michael Nally serves as Chief Executive Officer and Flagship Pioneering CEO-Partner. The company was co-founded by Molly Gibson and Gevorg Grigoryan. The Board of Directors is chaired by Noubar Afeyan (Founder and CEO of Flagship Pioneering) and includes distinguished members such as Frances Arnold (Nobel Laureate in Chemistry) and Stéphane Bancel (CEO of Moderna). ### **Ethics and Responsible Innovation** Generate:Biomedicines is a signatory to the Responsible AI x Biodesign initiative, advocating the responsible use of artificial intelligence in biotechnology. The company collaborates with regulatory agencies and academic institutions to advance ethical and safety standards for AI-enabled biodesign. ### **Infrastructure** In addition to its headquarters in Somerville, Generate operates research and development facilities in Boynton Yards and Andover, Massachusetts, encompassing over 140,000 square feet of laboratory and computational infrastructure. Across these facilities, more than 42,000 protein sequences have been generated, analyzed, and tested. The company integrates wet-lab experimentation and computational modeling under one roof to create a unified environment for rapid biological design and validation. ## Academic Sources and References 1. Generate Biomedicines. “About Us.” Official Website. Accessed October 23, 2025. https://generatebiomedicines.com/about-us.Generate Biomedicines. “Generative Biology.” Official Website. Accessed October 23, 2025. https://generatebiomedicines.com/generative-biology.Generate Biomedicines. “Home.” Official Website. Accessed October 23, 2025. https://generatebiomedicines.com/.Generate Biomedicines. “Pipeline.” Official Website. Accessed October 23, 2025. https://generatebiomedicines.com/pipeline.Generate Biomedicines. “Platform.” Official Website. Accessed October 23, 2025. https://generatebiomedicines.com/platform.Generate Biomedicines. “About.” LinkedIn. Accessed October 23, 2025. https://www.linkedin.com/company/generate-biomedicines/.